Biblio
.
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. J Clin Oncol. 2023:JCO2201630.
CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany. Blood Adv. 2023.
Excellent outcome of stem cell transplantation for sickle cell disease. Ann Hematol. 2023.
. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. Br J Cancer. 2023.
Th1 cytokines in pediatric acute lymphoblastic leukemia. Cancer Immunol Immunother. 2023.
.